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Abstract
Background: Premature death of Plasmodium-infected erythrocytes is considered to favourably influence the clinical 
course of malaria. Aurothiomalate has previously been shown to trigger erythrocyte death or eryptosis, which is 
characterized by cell membrane scrambling leading to phosphatidylserine exposure at the cell surface. 
Phosphatidylserine-exposing cells are rapidly cleared from circulating blood. The present study thus tested whether 
sodium aurothiomalate influences the intraerythrocytic parasite development in vitro and the clinical course of murine 
malaria in vivo.
Methods: Human erythrocytes were infected with Plasmodium falciparum BinH in vitro and mice were infected 
(intraperitoneal injection of 1 × 106 parasitized murine erythrocytes) with Plasmodium berghei ANKA in vivo.
Results: Exposure to aurothiomalate significantly decreased the in vitro parasitemia of P. falciparum-infected human 
erythrocytes without influencing the intraerythrocytic DNA/RNA content. Administration of sodium aurothiomalate in 
vivo (daily 10 mg/kg b.w. s.c. from the 8th day of infection) enhanced the percentage of phosphatidylserine-exposing 
infected and noninfected erythrocytes in blood. All nontreated mice died within 30 days of infection. Aurothiomalate-
treatment delayed the lethal course of malaria leading to survival of more than 50% of the mice 30 days after infection.
Conclusions: Sodium aurothiomalate influences the survival of Plasmodium berghei-infected mice, an effect only 
partially explained by stimulation of eryptosis.
Background
The malaria pathogen Plasmodium  imposes oxidative
stress on infected cells [1], which in turn elicits eryptosis,
a form of erythrocyte death [2-4]. The signaling leading
to cell membrane scrambling includes an increase in the
cytosolic Ca2+ activity [5-10] and/or formation of cer-
amide and/or formation of ceramide [11]. Ca2+ further
stimulates Ca2+-sensitive K+  channels [10,12-18]. The
Ca2+-permeable cation channels are activated by oxida-
tive stress [19,20]. Oxidative stress [21] and excessive
cytosolic Ca2+ concentrations [22] are known to similarly
trigger cell membrane scrambling or apoptosis in nucle-
ated cells.
Phosphatidylserine-exposing cells are recognized by
macrophages [23,24], phagocytosed [25,26] and thus rap-
idly cleared from circulating blood [27].
In malaria, accelerated clearance of infected erythro-
cytes [28] may counteract the development of para-
sitemia [29-31], in genetic erythrocyte disorders [9,32-
36], in iron deficiency [2], or following treatment with
lead [3], chlorpromazine [37], azathioprine [38] or
cyclosporine [39]. The erythrocyte cation channel is
inhibited by erythropoietin [40] and may favourably
influence the course of malaria [15]. Eryptosis is further
inhibited by erythropoietin [41], caffeine [42] and thymol
[43].
Eryptosis is stimulated by aurothiomalate, a gold-con-
taining drug effective against rheumatoid arthritis [44].
Gold complexes have indeed been shown to counteract
malaria [45-51]. They are considered to be effective
through inhibition of heme aggregation, haemozoin for-
mation and/or parasitic thioredoxin reductase as well as
interaction with the DNA of the parasite [52-57].
The present study explored, whether sodium auro-
thiomalate augments the death of Plasmodium falci-
parum-infected human erythrocytes and/or Plasmodium
berghei-infected mouse erythrocytes and whether this
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effect correlates with a favourable influence on para-
sitemia and host survival during murine malaria.
Methods
Human erythrocytes were drawn from healthy volun-
teers. The study was approved by the Ethical commission
of the University of Tübingen.
Animal experiments were performed according to the
German animal protection law and approved by the local
authorities (registration number PY 4/09). Experiments
were performed in healthy SV129/J wild type mice (aged
4 months, both male and female). The animals had free
access to standard chow (C1310, Altromin, Lage, Ger-
many) and drinking water. Blood was drawn by incision
of the tail vein.
For infection of human erythrocytes the human patho-
gen Plasmodium falciparum (P. falciparum) strain BinH
[58] was grown in vitro [37,59]. Parasites were cultured as
described earlier [60-62] at a hematocrit of 2% and a par-
asitemia of 2-10% in RPMI 1640 medium supplemented
with Albumax II (0.5%; Gibco, Karlsruhe, Germany) in an
atmosphere of 90% N2, 5% CO2 and 5% O2 [62,63].
To estimate the in vitro growth of Plasmodium falci-
parum the BinH strain was cultured and synchronized to
the ring stage by sorbitol treatment as described previ-
ously [14,63]. For the in vitro growth assay, synchronized
parasitized erythrocytes were aliquoted in 96-well plates
(200 μl aliquots, 1% hematocrit, 0.5-2% parasitemia) and
grown for 48 h in the presence or absence of sodium
aurothiomalate.
The parasitemia was assessed 0 h and 48 h after infec-
t i o n  b y  fl o w  cyt o m e t ry  o f  h u m a n  e ryt h r ocyt es  a n d  b y
counting of Giemsa-stained blood smears from infected
mice. Parasitemia was defined as the percentage of eryth-
rocytes stained with the DNA/RNA-specific fluorescence
dye Syto16 or by identification of Giemsa-stained
infected erythrocytes using light microscopy.
For Giemsa staining, the thick blood film was air-dried
and fixed with methanol. 2% Giemsa solution (Sigma)
was added for 30 min. The slide was rinsed with water
and again dried. Then, the slides were analysed under a
Leica CM E light microscope (100 ×, oil immersion).
To estimate DNA/RNA amplification of the intraeryth-
rocytic parasite, the culture was ring stage-synchronized
and re-synchronized after 6 h of culture (to narrow the
developmental parasite stage), aliquoted (200 μl aliquots,
2% hematocrit and 10% parasitemia) and cultured for fur-
ther 16 h in the presence or absence of sodium auro-
thiomalate. Thereafter, the DNA/RNA amount of the
parasitized erythrocytes was determined by Syto16 fluo-
rescence as a measure of intraerythrocytic parasite cop-
ies.
For infection of mice Plasmodium berghei ANKA-para-
sitized murine erythrocytes (1 × 106) were injected intra-
peritoneally [64,65]. Where indicated, sodium
aurothiomalate (10 mg/kg b.w. s.c) was administered
from the 8th day of infection daily. Blood was collected
from the mice daily starting 8 days after infection by inci-
sion of the tail. The hematocrit was determined by cen-
trifugation in hematocrit capillaries. Parasitemia was
determined by Syto16 staining in FACS analysis. In vitro
experiments were performed at 37°C in Ringer solution
containing (in mM) 125 NaCl, 5 KCl, 1 MgSO4, 32 N-2-
hydroxyethylpiperazine-N-2-ethanesulfonic acid
(HEPES)/NaOH (pH 7.4), 5 glucose, 1 CaCl2 [66]. Auro-
thiomalate was added to the NaCl Ringer at final concen-
trations varying from 0.1 to 100 μM (Sigma, Schnelldorf,
Germany). For in vitro treatment, the final hematocrit
was adjusted to 0.3%.
For determination of phosphatidylserine exposure,
FACS analysis was performed as described [10]. After
incubation in the presence or absence of sodium auro-
thiomalate, suspensions of Plasmodium falciparum-
infected erythrocytes were stained with annexin V-APC
(BD Biosciences Pharmingen, Heidelberg, Germany) and/
or with Syto16 (Molecular Probes, Göttingen, Germany)
to identify phosphatidylserine-exposing and infected
erythrocytes, respectively. For annexin V-binding, eryth-
rocytes were washed, resuspended in annexin V-binding
buffer (Ringer solution containing 5 mM CaCl2. pH 7.4),
stained with annexin V-APC (dilution 1:20), incubated
for 20 min at room temperature, and diluted 1:5 with
annexin V-binding buffer. Syto16 (final concentration of
20 nM) was added directly to the diluted erythrocyte sus-
pension or co-incubated in the annexin V-containing buf-
fer solution. Erythrocytes were analyzed by flow
cytometry (FACS-Calibur, Becton Dickinson, Heidelberg,
Germany) in fluorescence channel FL-1 for Syto16
(detected at 530 nm) and in FL-4 for annexin V-APC flu-
orescence intensity (detected at 660 nm).
Data are expressed as arithmetic means ± SEM, and
statistical analysis was made by t-test or ANOVA using
Tukey's test as post hoc test, as appropriate. p < 0.05 was
considered as statistically significant.
Results and Discussion
A first series of experiments explored the influence of
aurothiomalate on the in vitro growth of Plasmodium fal-
ciparum  in human erythrocytes. To this end, P. falci-
parum-infected erythrocytes were cultured in human
erythrocytes and synchronized to the ring stage by sorbi-
tol treatment. Within 48 hours the percentage of infected
erythrocytes increased from 6.0% to 21.0% in the absence
and to 9.8% in the presence of 100 μM aurothiomalate
(Fig. 1A). Accordingly, aurothiomalate blunted the
increase in the percentage of parasitized erythrocytes, an
effect reaching statistical significance at ≥ 10 μM auro-Alesutan et al. Malaria Journal 2010, 9:118
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thiomalate (Fig. 1A). The halfmaximal inhibition (IC50)
was achieved by 68 μM aurothiomalate. In contrast, at the
concentrations tested, the presence of aurothiomalate did
not influence the intraerythrocytic DNA amplification of
the parasite (Fig. 1AB).
In order to determine the effect of infection and of
aurothiomalate on eryptosis, phosphatidylserine-expos-
ing erythrocytes were identified by measurement of
annexin V-binding in FACS analysis. Within 24 hours, the
infection with P. falciparum markedly increased the
annexin V-binding of infected and noninfected erythro-
cytes (Fig. 2). The percentage of annexin V-binding was,
however, significantly higher in infected than in nonin-
fected erythrocytes (Fig. 2). The phosphatidylserine
exposure of infected erythrocytes was significantly
increased in the presence of aurothiomalate (Fig. 2), an
effect reaching statistical significance at 50 μM auro-
thiomalate.
In a next series, mice were infected with P. berghei with
or without sodium aurothiomalate treatment. Sodium
aurothiomalate was administered daily from the 8th day of
infection. Similar to the in vitro infection of human
erythrocytes with P. falciparum, the infection of mice
with P. berghei was followed by a marked increase in the
percentage of phosphatidylserine-exposing erythrocytes.
Figure 1 Effects of sodium aurothiomalate on intraerythrocytic amplification and in vitro parasitemia. A. In vitro parasitemia with P. falciparum 
(left panel) in human erythrocytes as a function of the aurothiomalate concentration (arithmetic means ± SEM, n = 16). *, *** indicate significant dif-
ference (p < 0.05, p < 0.001) from the absence of aurothiomalate. Intraerythrocytic DNA amplification (right panel) as a function of the aurothiomalate 
concentration (arithmetic means ± SEM, n = 12). B. Intraerythrocytic DNA amplification (right panel) as in B for different time periods (arithmetic means 
± SEM, n = 8).Alesutan et al. Malaria Journal 2010, 9:118
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The phosphatidylserine exposure of infected erythro-
cytes was significantly more pronounced following treat-
ment with sodium aurothiomalate than the
phosphatidylserine exposure of noninfected erythrocytes
(Fig. 3).
The parasitemia was still low on the 8th day of infection
(Fig. 4B). The percentage of infected erythrocytes gradu-
ally increased with or without sodium aurothiomalate
treatment. However, the percentage of parasitized eryth-
rocytes was significantly lower in sodium auro-
thiomalate-treated animals than in animals without
sodium aurothiomalate treatment (Fig. 4A, B).
Since the FACS-dependent determination of para-
sitemia utilizes a DNA/RNA-specific dye, reticulocytes
may also be counted as parasitized erythrocytes. There-
fore, a second series of experiments was performed to
compare the values for parasitemia determined by FACS
analysis to those obtained from Giemsa staining. As
shown in Fig. 4D, E, parasitemia was lower in the auro-
thiomalate-treated group of mice, irrespective of the
methods applied.
The treatment with sodium aurothiomalate further
resulted in enhanced survival of P. berghei-infected mice.
As shown in Fig. 4C, all untreated animals died within 30
days after the infection. In contrast, 57% of the sodium
aurothiomalate-treated animals were still alive 30 days
after infection. All treated mice died, however, until day
44 after infection.
To investigate whether aurothiomalate treatment influ-
ences inflammation, the plasma levels of the inflamma-
tory mediator TNFα, were determined on the 16th day of
infection. As a result, the TNFα concentration in non-
treated mice was 53.4 ± 29.7 pg/ml whereas the TNFα
was below the detection limit in mice treated with
sodium aurothiomalate (both n = 4).
As shown earlier, TNF-α may exert an antiparasitic
effect in animal models [67-69], and high TNF produc-
tion is associated with more rapid clinical and parasito-
logic recovery in humans [70]. Even though
aurothiomalate does not seem to affect induction of
TNF-alpha in phagocytic cell cultures [71], the present
observations clearly demonstrate an effect of the drug on
TNF production in vivo.
Malaria is paralleled by loss of erythrocytes leading to
anemia. As shown in Fig. 5, the hematocrit of auro-
thiomalate-treated mice was significantly reduced. The
effect could have been due to enhanced eryptosis or
hemolysis. In noninfected erythrocytes aurothiomalate
has previously been shown to trigger eryptosis rather
than hemolysis [44].
The present study demonstrates that aurothiomalate
had only mild effects on the parasite burden and moder-
ately delayed the lethal course of malaria following infec-
tion of mice with P. berghei. Similar to what has been
observed earlier [64], the infection of mice with P. berghei
w a s  f o l l o w e d  b y  a n  i n v a r i a b l y  l e t h a l  c o u r s e  o f  m a l a r i a
Figure 3 Effect of sodium aurothiomalate treatment on phos-
phatidylserine exposure of infected and non-infected erythro-
cytes from Plasmodium berghei-infected mice. Arithmetic means ± 
SEM (n = 6-8) of the percentage of phosphatidylserine-exposing in-
fected (right bars) and non-infected (left bars) erythrocytes taken from 
animals without (black bars) and with (white bars) sodium auro-
thiomalate treatment (daily 10 mg/kg b.w. s.c.) on the 22nd day after in-
fection. ### indicates significant difference (p < 0.001) from absence of 
sodium aurothiomalate. *** indicates significant difference (p < 0.001) 
from noninfected erythrocytes.
Figure 2 Effects of aurothiomalate on phosphatidylserine expo-
sure of infected and noninfected human erythrocytes. Arithmetic 
means ± SEM (n = 6) of the percentage of annexin V-binding infected 
(open bars) and non-infected (closed bars) erythrocytes following in-
fection of human erythrocytes with P. falciparum in the presence of 0 - 
100 μM aurothiomalate. ##, ### indicate significant difference (p < 0.01, 
p < 0.001) from non-infected erythrocytes, **, *** indicate significant 
difference (p < 0.01, p < 0.001) from the absence of aurothiomalate.Alesutan et al. Malaria Journal 2010, 9:118
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without aurothiomalate treatment. More than 50% of the
sodium aurothiomalate-treated animals survived the
infection for 30 days, even though they all died until day
44.
The effect of sodium aurothiomalate treatment may in
part be due to a toxic effect on the pathogen, which com-
promises the intraerythrocyte growth of the parasite. As
a matter of fact, gold-containing drugs have previously
been shown to be toxic for Plasmodia  [45-57]. Drugs
could specifically enter infected erythrocytes, as the
pathogen dramatically enhances the permeability of the
erythrocyte membrane [1].
Alternatively, sodium aurothiomalate may exert a pro-
tective effect by accelerating the death of infected eryth-
rocytes. Phosphatidylserine-exposing erythrocytes are
engulfed by macrophages [25,26] and are thus rapidly
cleared from circulating blood [27]. As eryptosis mainly
affects infected erythrocytes, accelerated eryptosis
should decrease the parasitemia and thus favourably
influence the course of the disease [29]. On the other
hand, eryptosis has been suggested to foster vascular
derangements of metabolic syndrome [72].
The discrepancy between the moderate influence of
aurothiomalate on parasitemia and the effect on survival
of the infected host is suggestive for an additional effect
of the drug on mouse survival. Possibly it is in part the
anti-inflammatory effect of the drug, which accounts for
at least part of the effect on host survival and the stimula-
tion of eryptosis. As a matter of fact, aurothiomalate
Figure 4 Effect of sodium aurothiomalate treatment on the parasitemia and survival of Plasmodium berghei-infected mice. A: Original his-
tograms of parasitemia-dependent Syto16 fluorescence in untreated animals (upper panels) and in animals treated daily from day 8 daily with 10 mg/
kg b.w. sodium aurothiomalate s.c. (lower panels) 10 (left panels) and 20 (right panels) days after infection with P. berghei. B: Arithmetic means ± SEM 
of the parasitemia in mice without treatment (open circles, n = 8 mice) or with daily 10 mg/kg b.w. s.c. of sodium aurothiomalate (closed circles, n = 
6 mice) as a function of days after infection with P. berghei. Significant difference (* p < 0.05, ** p < 0.01, *** p < 0.001; t-test) from the untreated animals 
on days 12 - 20. The results presented are one of three independent series. C: Survival of mice without treatment (open circles) or with daily 10 mg/
kg b.w. sodium aurothiomalate s.c. (closed circles) as a function of days after infection with Plasmodium berghei. D-E: Arithmetic means ± SEM of the 
parasitemia in mice without treatment (open circles, n = 4 mice) or with daily 10 mg/kg b.w. s.c. of sodium aurothiomalate (closed circles, n = 4 mice) 
as a function of days after infection with P. berghei. The parasitemia was determined daily either by staining with Syto16 and subsequent FACS analysis 
as in B (D) or by daily Giemsa staining of blood smears and light microscopy-dependent analysis (E).
A
104
104
C
e
l
l
 
c
o
u
n
t
s
0
100 101 102 103 104
200
100 101 102 103
0
200
Syto-16 fluorescence
100 101 102 103
200
100 101 102 103 104
0
200
0
48.82 14.45
10.77 32,44
B
C
0
20
40
60
80
100
8 12 162 02 42 83 23 64 04 4
days after infection
s
u
r
v
i
v
a
l
[
%
]
control
aurothiomalate
0
15
30
45
60
75
8 10 12 14 16 182 02 2
days after infection
p
a
r
a
s
i
t
e
m
i
a
(
%
)
control
aurothiomalate
0
8
16
24
32
40
48
56
8 10 12 14 16 182 02 2
days after infection
p
a
r
a
s
i
t
e
m
i
a
(
%
)
0
8
16
24
32
40
8 10 12 14 16 182 02 2
days after infection
p
a
r
a
s
i
t
e
m
i
a
(
%
)
control
aurothiomalate
control
aurothiomalate
E
D
*** *** ***
** *
*
*
**Alesutan et al. Malaria Journal 2010, 9:118
http://www.malariajournal.com/content/9/1/118
Page 6 of 8
treatment virtually abolished the increase in TNFα
plasma concentration following infection.
Conclusion
In mice, sodium aurothiomalate delays the lethal course
of malaria. Presumably, the effect is not only due to the
toxicity for the pathogen and due to stimulation of eryp-
tosis, but may involve the anti-inflammatory activity of
the drug.
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